Wall Street analyst estimates for Option Care Health, Inc. (OPCH): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Option Care Health, Inc. delivers infusion services to patients in their homes and other non-hospital settings throughout the United States. The company offers a broad spectrum of specialized infusion treatments, including therapies for various infections, management of heart failure, and comprehensive nutritional support (both intravenous and tube feeding) for individuals with acute or chronic conditions such as stroke, cancer, and digestive illnesses.
Consensus price target
$28.78 (-10 % vs price $31.83)
between $22.00 and $32.05 · 4 targets published in the last quarter
Closing price, Oct 30
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $5.8B | $5.7B – $5.8B | $1.88 | 8 |
| 2027E | $6.1B | $6.1B – $6.2B | $2.08 | 8 |
| 2028E | $6.6B | $6.5B – $6.7B | $2.32 | 6 |
Figures in USD · consensus as of November 1, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 10 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 16 |
| Avg rating (−2 sell to +2 buy) | 0.38 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-04 | $0.49 | ||
| 2026-07-29 | $0.45 | $0.43 | +5.6% |
| 2026-04-30 | $0.40 | $0.37 | +8.1% |
| 2026-02-24 | $0.46 | $0.46 | +0.0% |
| 2025-10-30 | $0.45 | $0.43 | +4.7% |
| 2025-07-30 | $0.41 | $0.40 | +2.5% |
| 2025-04-29 | $0.40 | $0.36 | +11.1% |
| 2025-02-26 | $0.35 | $0.33 | +6.1% |
Valuation Ratios
| P/E Ratio | 23.93 |
| Price / Book | 3.91 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $935.6M | $817.2M | $1.94B | $2.31B | $3.03B | $3.44B | $3.94B | $4.30B | $5.00B | $5.65B |
| Cost of Revenue | $673.5M | $547.9M | $1.52B | $1.80B | $2.35B | $2.66B | $3.08B | $3.32B | $3.99B | $4.63B |
| Gross Profit | $262.1M | $269.2M | $422.2M | $513.0M | $682.3M | $779.6M | $866.9M | $981.2M | $1.01B | $1.02B |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | $38.8M | $39.6M | $345.9M | $459.6M | $500.2M | $525.7M | $566.1M | $607.4M | $630.3M | $682.5M |
| Operating Expenses | $298.3M | $332.5M | $383.9M | $513.3M | $571.5M | $588.8M | $626.7M | $666.6M | $691.2M | $682.5M |
| Operating Income | -$36.2M | -$63.3M | $38.3M | -$319,000 | $110.8M | $190.8M | $240.2M | $314.6M | $321.8M | $337.9M |
| EBITDA | $53.5M | $66.3M | $78.1M | $53.4M | $180.4M | $252.3M | $325.0M | $472.2M | $396.1M | $416.8M |
| Interest Expense | $37.6M | $52.1M | $46.1M | $73.4M | $91.2M | $55.5M | $54.9M | $62.2M | $60.6M | $63.2M |
| Pre-tax Income | -$34.2M | -$67.4M | -$8.8M | -$78.2M | -$5.2M | $116.5M | $205.8M | $358.7M | $283.6M | $282.9M |
| Income Tax | $2.0M | -$4.1M | -$2.7M | -$2.3M | $2.8M | -$23.4M | $55.2M | $91.7M | $71.8M | $75.3M |
| Net Income | -$42.8M | -$64.2M | -$6.1M | -$75.9M | -$8.1M | $139.9M | $150.6M | $267.1M | $211.8M | $207.6M |
| EPS | -$1.77 | -$2.02 | -$1.62 | -$0.49 | -$0.04 | $0.78 | $0.83 | $1.49 | $1.23 | $1.28 |
| EPS (Diluted) | -$1.77 | -$2.02 | -$1.62 | -$0.49 | -$0.04 | $0.77 | $0.83 | $1.48 | $1.23 | $1.27 |
| Shares Outstanding (Diluted) | 23.4 M | 30.9 M | 32.0 M | 156.3 M | 181.0 M | 181.2 M | 182.1 M | 180.4 M | 172.8 M | 163.4 M |
Price
| Price | $31.83 (closing price, October 30, 2026) |
| Market Cap | $4.8B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ENSG · AVAH · EHC · CHE
Explore sector: Healthcare · Medical - Care Facilities
More sections of OPCH: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks